nodes	percent_of_prediction	percent_of_DWPC	metapath
Methyl aminolevulinate—FCGR1A—Antigen processing-Cross presentation—PDIA3—prostate cancer	0.0136	0.0426	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Interferon gamma signaling—MT2A—prostate cancer	0.0118	0.037	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Role of phospholipids in phagocytosis—ITPR1—prostate cancer	0.0113	0.0356	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Regulation of actin dynamics for phagocytic cup formation—HSP90AB1—prostate cancer	0.0108	0.0341	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Interferon Signaling—RNASEL—prostate cancer	0.0102	0.0321	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Fcgamma receptor (FCGR) dependent phagocytosis—HSP90AB1—prostate cancer	0.00818	0.0257	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—FCGR activation—SRC—prostate cancer	0.00814	0.0256	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Interferon gamma signaling—B2M—prostate cancer	0.00721	0.0226	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—RNASEL—prostate cancer	0.00683	0.0214	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Antigen processing-Cross presentation—B2M—prostate cancer	0.0064	0.0201	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Class I MHC mediated antigen processing & presentation—FBXO44—prostate cancer	0.00616	0.0193	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Regulation of actin dynamics for phagocytic cup formation—VAV3—prostate cancer	0.00604	0.019	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Role of phospholipids in phagocytosis—PIK3CB—prostate cancer	0.00602	0.0189	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Antigen processing-Cross presentation—CALR—prostate cancer	0.0058	0.0182	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Interferon Signaling—MT2A—prostate cancer	0.00576	0.0181	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Class I MHC mediated antigen processing & presentation—PDIA3—prostate cancer	0.00542	0.017	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Fcgamma receptor (FCGR) dependent phagocytosis—VAV3—prostate cancer	0.00456	0.0143	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Fcgamma receptor (FCGR) dependent phagocytosis—ITPR1—prostate cancer	0.00442	0.0139	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Interferon Signaling—EIF2AK2—prostate cancer	0.00437	0.0137	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—IRAK4—prostate cancer	0.00385	0.0121	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—MT2A—prostate cancer	0.00385	0.0121	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Role of phospholipids in phagocytosis—PIK3CA—prostate cancer	0.00367	0.0115	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Interferon gamma signaling—ICAM1—prostate cancer	0.00363	0.0114	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Interferon Signaling—B2M—prostate cancer	0.00352	0.0111	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—GHR—prostate cancer	0.00348	0.0109	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—FBXO44—prostate cancer	0.00305	0.00957	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—EIF2AK2—prostate cancer	0.00292	0.00916	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Interferon gamma signaling—JAK2—prostate cancer	0.00281	0.00884	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Interferon Signaling—EGR1—prostate cancer	0.00278	0.00873	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—PDIA3—prostate cancer	0.00268	0.00843	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Class I MHC mediated antigen processing & presentation—B2M—prostate cancer	0.00256	0.00803	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—TLR5—prostate cancer	0.00254	0.00797	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—DEFB1—prostate cancer	0.0024	0.00755	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Fcgamma receptor (FCGR) dependent phagocytosis—PIK3CB—prostate cancer	0.00235	0.00738	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—B2M—prostate cancer	0.00235	0.00738	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Class I MHC mediated antigen processing & presentation—CALR—prostate cancer	0.00232	0.00728	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—RNASEL—prostate cancer	0.00223	0.00701	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—TIRAP—prostate cancer	0.0022	0.00691	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—IRAK4—prostate cancer	0.00216	0.00677	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—IL1RN—prostate cancer	0.00214	0.00672	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—HSP90B1—prostate cancer	0.00204	0.00642	CbGpPWpGaD
Methyl aminolevulinate—Dizziness—Nilutamide—prostate cancer	0.00197	0.00288	CcSEcCtD
Methyl aminolevulinate—Eye disorder—Goserelin—prostate cancer	0.00196	0.00288	CcSEcCtD
Methyl aminolevulinate—Dizziness—Flutamide—prostate cancer	0.00196	0.00287	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Degarelix—prostate cancer	0.00196	0.00287	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—TLR6—prostate cancer	0.00195	0.00613	CbGpPWpGaD
Methyl aminolevulinate—Ulcer—Prednisone—prostate cancer	0.00195	0.00286	CcSEcCtD
Methyl aminolevulinate—Eye disorder—Conjugated Estrogens—prostate cancer	0.00195	0.00285	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Bicalutamide—prostate cancer	0.00193	0.00283	CcSEcCtD
Methyl aminolevulinate—Burning sensation—Doxorubicin—prostate cancer	0.00192	0.00282	CcSEcCtD
Methyl aminolevulinate—Asthenia—Degarelix—prostate cancer	0.00191	0.0028	CcSEcCtD
Methyl aminolevulinate—Nausea—Estrone—prostate cancer	0.0019	0.00279	CcSEcCtD
Methyl aminolevulinate—Photosensitivity reaction—Estradiol—prostate cancer	0.0019	0.00279	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Fcgamma receptor (FCGR) dependent phagocytosis—SRC—prostate cancer	0.00188	0.00592	CbGpPWpGaD
Methyl aminolevulinate—Pruritus—Degarelix—prostate cancer	0.00188	0.00276	CcSEcCtD
Methyl aminolevulinate—Rash—Nilutamide—prostate cancer	0.00187	0.00275	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Nilutamide—prostate cancer	0.00187	0.00275	CcSEcCtD
Methyl aminolevulinate—Discomfort—Ethinyl Estradiol—prostate cancer	0.00187	0.00274	CcSEcCtD
Methyl aminolevulinate—Rash—Flutamide—prostate cancer	0.00187	0.00274	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Flutamide—prostate cancer	0.00186	0.00274	CcSEcCtD
Methyl aminolevulinate—Headache—Nilutamide—prostate cancer	0.00186	0.00273	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—EGR1—prostate cancer	0.00186	0.00583	CbGpPWpGaD
Methyl aminolevulinate—Headache—Flutamide—prostate cancer	0.00185	0.00272	CcSEcCtD
Methyl aminolevulinate—Skin ulcer—Epirubicin—prostate cancer	0.00185	0.00272	CcSEcCtD
Methyl aminolevulinate—Fatigue—Bicalutamide—prostate cancer	0.00185	0.00271	CcSEcCtD
Methyl aminolevulinate—Blister—Doxorubicin—prostate cancer	0.00185	0.00271	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—FBXO44—prostate cancer	0.00185	0.00581	CbGpPWpGaD
Methyl aminolevulinate—Dizziness—Estradiol valerate/Dienogest—prostate cancer	0.00185	0.00271	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Cabazitaxel—prostate cancer	0.00184	0.0027	CcSEcCtD
Methyl aminolevulinate—Pain—Bicalutamide—prostate cancer	0.00184	0.00269	CcSEcCtD
Methyl aminolevulinate—Erythema—Goserelin—prostate cancer	0.00183	0.00268	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—MAP3K7—prostate cancer	0.00182	0.00572	CbGpPWpGaD
Methyl aminolevulinate—Oedema—Ethinyl Estradiol—prostate cancer	0.00181	0.00266	CcSEcCtD
Methyl aminolevulinate—Erythema—Conjugated Estrogens—prostate cancer	0.00181	0.00266	CcSEcCtD
Methyl aminolevulinate—Rash pustular—Epirubicin—prostate cancer	0.00181	0.00265	CcSEcCtD
Methyl aminolevulinate—Infection—Ethinyl Estradiol—prostate cancer	0.0018	0.00264	CcSEcCtD
Methyl aminolevulinate—Asthenia—Cabazitaxel—prostate cancer	0.0018	0.00263	CcSEcCtD
Methyl aminolevulinate—Stinging—Epirubicin—prostate cancer	0.00178	0.00261	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Interferon Signaling—ICAM1—prostate cancer	0.00177	0.00557	CbGpPWpGaD
Methyl aminolevulinate—Nausea—Nilutamide—prostate cancer	0.00177	0.00259	CcSEcCtD
Methyl aminolevulinate—Rash—Estradiol valerate/Dienogest—prostate cancer	0.00176	0.00258	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Estradiol valerate/Dienogest—prostate cancer	0.00176	0.00258	CcSEcCtD
Methyl aminolevulinate—Skin exfoliation—Prednisone—prostate cancer	0.00176	0.00258	CcSEcCtD
Methyl aminolevulinate—Swelling—Docetaxel—prostate cancer	0.00176	0.00258	CcSEcCtD
Methyl aminolevulinate—Nausea—Flutamide—prostate cancer	0.00176	0.00258	CcSEcCtD
Methyl aminolevulinate—Dizziness—Degarelix—prostate cancer	0.00176	0.00258	CcSEcCtD
Methyl aminolevulinate—Headache—Estradiol valerate/Dienogest—prostate cancer	0.00175	0.00257	CcSEcCtD
Methyl aminolevulinate—Skin ulcer—Doxorubicin—prostate cancer	0.00171	0.00251	CcSEcCtD
Methyl aminolevulinate—Urticaria—Bicalutamide—prostate cancer	0.00171	0.0025	CcSEcCtD
Methyl aminolevulinate—Swelling—Capecitabine—prostate cancer	0.0017	0.0025	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—HSP90AB1—prostate cancer	0.0017	0.00534	CbGpPWpGaD
Methyl aminolevulinate—Rash—Degarelix—prostate cancer	0.00167	0.00246	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Degarelix—prostate cancer	0.00167	0.00245	CcSEcCtD
Methyl aminolevulinate—Rash pustular—Doxorubicin—prostate cancer	0.00167	0.00245	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—PRKDC—prostate cancer	0.00167	0.00524	CbGpPWpGaD
Methyl aminolevulinate—Headache—Degarelix—prostate cancer	0.00166	0.00244	CcSEcCtD
Methyl aminolevulinate—Eye pain—Capecitabine—prostate cancer	0.00166	0.00244	CcSEcCtD
Methyl aminolevulinate—Nausea—Estradiol valerate/Dienogest—prostate cancer	0.00166	0.00243	CcSEcCtD
Methyl aminolevulinate—Dizziness—Cabazitaxel—prostate cancer	0.00165	0.00243	CcSEcCtD
Methyl aminolevulinate—Stinging—Doxorubicin—prostate cancer	0.00165	0.00242	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—PDIA3—prostate cancer	0.00163	0.00511	CbGpPWpGaD
Methyl aminolevulinate—Dermatitis bullous—Docetaxel—prostate cancer	0.00162	0.00238	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Bicalutamide—prostate cancer	0.00158	0.00232	CcSEcCtD
Methyl aminolevulinate—Nausea—Degarelix—prostate cancer	0.00158	0.00231	CcSEcCtD
Methyl aminolevulinate—Dermatitis bullous—Capecitabine—prostate cancer	0.00157	0.00231	CcSEcCtD
Methyl aminolevulinate—Headache—Cabazitaxel—prostate cancer	0.00157	0.0023	CcSEcCtD
Methyl aminolevulinate—Fatigue—Ethinyl Estradiol—prostate cancer	0.00156	0.00229	CcSEcCtD
Methyl aminolevulinate—Eye disorder—Estradiol—prostate cancer	0.00156	0.00228	CcSEcCtD
Methyl aminolevulinate—Asthenia—Bicalutamide—prostate cancer	0.00154	0.00226	CcSEcCtD
Methyl aminolevulinate—Discomfort—Goserelin—prostate cancer	0.00154	0.00226	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—IL18—prostate cancer	0.00154	0.00483	CbGpPWpGaD
Methyl aminolevulinate—Ulcer—Epirubicin—prostate cancer	0.00152	0.00224	CcSEcCtD
Methyl aminolevulinate—Pruritus—Bicalutamide—prostate cancer	0.00152	0.00223	CcSEcCtD
Methyl aminolevulinate—Oedema—Goserelin—prostate cancer	0.00149	0.00219	CcSEcCtD
Methyl aminolevulinate—Nausea—Cabazitaxel—prostate cancer	0.00149	0.00218	CcSEcCtD
Methyl aminolevulinate—Infection—Goserelin—prostate cancer	0.00148	0.00218	CcSEcCtD
Methyl aminolevulinate—Oedema—Conjugated Estrogens—prostate cancer	0.00148	0.00217	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—TLR5—prostate cancer	0.00148	0.00464	CbGpPWpGaD
Methyl aminolevulinate—Infection—Conjugated Estrogens—prostate cancer	0.00147	0.00216	CcSEcCtD
Methyl aminolevulinate—Erythema—Estradiol—prostate cancer	0.00145	0.00213	CcSEcCtD
Methyl aminolevulinate—Face oedema—Capecitabine—prostate cancer	0.00145	0.00213	CcSEcCtD
Methyl aminolevulinate—Urticaria—Ethinyl Estradiol—prostate cancer	0.00144	0.00211	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Fcgamma receptor (FCGR) dependent phagocytosis—PIK3CA—prostate cancer	0.00143	0.0045	CbGpPWpGaD
Methyl aminolevulinate—Dermatitis contact—Epirubicin—prostate cancer	0.00142	0.00209	CcSEcCtD
Methyl aminolevulinate—Dizziness—Bicalutamide—prostate cancer	0.00142	0.00208	CcSEcCtD
Methyl aminolevulinate—Ulcer—Doxorubicin—prostate cancer	0.00141	0.00207	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—DEFB1—prostate cancer	0.0014	0.0044	CbGpPWpGaD
Methyl aminolevulinate—Skin exfoliation—Epirubicin—prostate cancer	0.00138	0.00202	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Interferon Signaling—JAK2—prostate cancer	0.00137	0.00432	CbGpPWpGaD
Methyl aminolevulinate—Rash—Bicalutamide—prostate cancer	0.00135	0.00199	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Bicalutamide—prostate cancer	0.00135	0.00198	CcSEcCtD
Methyl aminolevulinate—Erythema—Mitoxantrone—prostate cancer	0.00135	0.00198	CcSEcCtD
Methyl aminolevulinate—Headache—Bicalutamide—prostate cancer	0.00134	0.00197	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Goserelin—prostate cancer	0.00134	0.00197	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Ethinyl Estradiol—prostate cancer	0.00134	0.00196	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Conjugated Estrogens—prostate cancer	0.00133	0.00195	CcSEcCtD
Methyl aminolevulinate—Dermatitis contact—Doxorubicin—prostate cancer	0.00132	0.00193	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—B2M—prostate cancer	0.00132	0.00414	CbGpPWpGaD
Methyl aminolevulinate—Asthenia—Ethinyl Estradiol—prostate cancer	0.0013	0.00191	CcSEcCtD
Methyl aminolevulinate—Face oedema—Prednisone—prostate cancer	0.00129	0.00189	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—PRKACB—prostate cancer	0.00129	0.00405	CbGpPWpGaD
Methyl aminolevulinate—Fatigue—Goserelin—prostate cancer	0.00129	0.00189	CcSEcCtD
Methyl aminolevulinate—Pruritus—Ethinyl Estradiol—prostate cancer	0.00128	0.00188	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—CTSB—prostate cancer	0.00128	0.00403	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—TIRAP—prostate cancer	0.00128	0.00402	CbGpPWpGaD
Methyl aminolevulinate—Pain—Goserelin—prostate cancer	0.00128	0.00187	CcSEcCtD
Methyl aminolevulinate—Fatigue—Conjugated Estrogens—prostate cancer	0.00128	0.00187	CcSEcCtD
Methyl aminolevulinate—Nausea—Bicalutamide—prostate cancer	0.00127	0.00187	CcSEcCtD
Methyl aminolevulinate—Skin exfoliation—Doxorubicin—prostate cancer	0.00127	0.00187	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—B2M—prostate cancer	0.00127	0.00397	CbGpPWpGaD
Methyl aminolevulinate—Pain—Conjugated Estrogens—prostate cancer	0.00126	0.00186	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—PPP3CA—prostate cancer	0.00126	0.00395	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—MT2A—prostate cancer	0.00126	0.00395	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—IRAK4—prostate cancer	0.00126	0.00395	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—PRKACB—prostate cancer	0.00124	0.00389	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—CTSB—prostate cancer	0.00123	0.00387	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—CTSD—prostate cancer	0.00123	0.00385	CbGpPWpGaD
Methyl aminolevulinate—Discomfort—Estradiol—prostate cancer	0.00122	0.00179	CcSEcCtD
Methyl aminolevulinate—Eye disorder—Etoposide—prostate cancer	0.00121	0.00177	CcSEcCtD
Methyl aminolevulinate—Dizziness—Ethinyl Estradiol—prostate cancer	0.0012	0.00176	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—HSP90B1—prostate cancer	0.00119	0.00374	CbGpPWpGaD
Methyl aminolevulinate—Urticaria—Goserelin—prostate cancer	0.00119	0.00174	CcSEcCtD
Methyl aminolevulinate—Photosensitivity reaction—Capecitabine—prostate cancer	0.00118	0.00174	CcSEcCtD
Methyl aminolevulinate—Oedema—Estradiol—prostate cancer	0.00118	0.00174	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—ICAM1—prostate cancer	0.00118	0.00372	CbGpPWpGaD
Methyl aminolevulinate—Infection—Estradiol—prostate cancer	0.00118	0.00173	CcSEcCtD
Methyl aminolevulinate—Urticaria—Conjugated Estrogens—prostate cancer	0.00117	0.00172	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—FGFR4—prostate cancer	0.00117	0.00369	CbGpPWpGaD
Methyl aminolevulinate—Eczema—Epirubicin—prostate cancer	0.00116	0.00171	CcSEcCtD
Methyl aminolevulinate—Eye pain—Epirubicin—prostate cancer	0.00116	0.0017	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—CALR—prostate cancer	0.00115	0.0036	CbGpPWpGaD
Methyl aminolevulinate—Rash—Ethinyl Estradiol—prostate cancer	0.00114	0.00168	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Ethinyl Estradiol—prostate cancer	0.00114	0.00168	CcSEcCtD
Methyl aminolevulinate—Discomfort—Mitoxantrone—prostate cancer	0.00114	0.00167	CcSEcCtD
Methyl aminolevulinate—Headache—Ethinyl Estradiol—prostate cancer	0.00114	0.00167	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—TLR6—prostate cancer	0.00114	0.00357	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—GHR—prostate cancer	0.00114	0.00357	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—FGFR4—prostate cancer	0.00113	0.00354	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—IRS1—prostate cancer	0.00112	0.00353	CbGpPWpGaD
Methyl aminolevulinate—Oedema—Mitoxantrone—prostate cancer	0.0011	0.00162	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Goserelin—prostate cancer	0.0011	0.00161	CcSEcCtD
Methyl aminolevulinate—Infection—Mitoxantrone—prostate cancer	0.0011	0.00161	CcSEcCtD
Methyl aminolevulinate—Dermatitis bullous—Epirubicin—prostate cancer	0.00109	0.00161	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Conjugated Estrogens—prostate cancer	0.00109	0.0016	CcSEcCtD
Methyl aminolevulinate—Nausea—Ethinyl Estradiol—prostate cancer	0.00108	0.00158	CcSEcCtD
Methyl aminolevulinate—Eczema—Doxorubicin—prostate cancer	0.00108	0.00158	CcSEcCtD
Methyl aminolevulinate—Eye pain—Doxorubicin—prostate cancer	0.00107	0.00157	CcSEcCtD
Methyl aminolevulinate—Asthenia—Goserelin—prostate cancer	0.00107	0.00157	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—CASP9—prostate cancer	0.00107	0.00335	CbGpPWpGaD
Methyl aminolevulinate—Paraesthesia—Estradiol—prostate cancer	0.00106	0.00156	CcSEcCtD
Methyl aminolevulinate—Asthenia—Conjugated Estrogens—prostate cancer	0.00106	0.00156	CcSEcCtD
Methyl aminolevulinate—Pruritus—Goserelin—prostate cancer	0.00106	0.00155	CcSEcCtD
Methyl aminolevulinate—Pruritus—Conjugated Estrogens—prostate cancer	0.00105	0.00154	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—PRKCQ—prostate cancer	0.00103	0.00325	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—CASP9—prostate cancer	0.00102	0.00322	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—MAP3K7—prostate cancer	0.00102	0.00321	CbGpPWpGaD
Methyl aminolevulinate—Fatigue—Estradiol—prostate cancer	0.00102	0.0015	CcSEcCtD
Methyl aminolevulinate—Dermatitis bullous—Doxorubicin—prostate cancer	0.00101	0.00149	CcSEcCtD
Methyl aminolevulinate—Pain—Estradiol—prostate cancer	0.00101	0.00148	CcSEcCtD
Methyl aminolevulinate—Face oedema—Epirubicin—prostate cancer	0.00101	0.00148	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—MAP2K1—prostate cancer	0.00101	0.00316	CbGpPWpGaD
Methyl aminolevulinate—Eye disorder—Docetaxel—prostate cancer	0.001	0.00147	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—PIK3CD—prostate cancer	0.001	0.00314	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—PRKCQ—prostate cancer	0.000993	0.00312	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—HSP90AB1—prostate cancer	0.000991	0.00311	CbGpPWpGaD
Methyl aminolevulinate—Paraesthesia—Mitoxantrone—prostate cancer	0.00099	0.00145	CcSEcCtD
Methyl aminolevulinate—Dizziness—Goserelin—prostate cancer	0.000987	0.00145	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—FGF10—prostate cancer	0.000982	0.00309	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—MAP3K7—prostate cancer	0.000981	0.00308	CbGpPWpGaD
Methyl aminolevulinate—Dizziness—Conjugated Estrogens—prostate cancer	0.000978	0.00143	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—PRKDC—prostate cancer	0.000971	0.00305	CbGpPWpGaD
Methyl aminolevulinate—Eye disorder—Capecitabine—prostate cancer	0.000971	0.00142	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—EIF2AK2—prostate cancer	0.000952	0.00299	CbGpPWpGaD
Methyl aminolevulinate—Fatigue—Mitoxantrone—prostate cancer	0.000951	0.00139	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—VAV3—prostate cancer	0.000948	0.00298	CbGpPWpGaD
Methyl aminolevulinate—Discomfort—Etoposide—prostate cancer	0.000945	0.00139	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—FGF10—prostate cancer	0.000943	0.00296	CbGpPWpGaD
Methyl aminolevulinate—Pain—Mitoxantrone—prostate cancer	0.000943	0.00138	CcSEcCtD
Methyl aminolevulinate—Rash—Goserelin—prostate cancer	0.000941	0.00138	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Goserelin—prostate cancer	0.000941	0.00138	CcSEcCtD
Methyl aminolevulinate—Urticaria—Estradiol—prostate cancer	0.00094	0.00138	CcSEcCtD
Methyl aminolevulinate—Headache—Goserelin—prostate cancer	0.000935	0.00137	CcSEcCtD
Methyl aminolevulinate—Face oedema—Doxorubicin—prostate cancer	0.000935	0.00137	CcSEcCtD
Methyl aminolevulinate—Erythema—Docetaxel—prostate cancer	0.000934	0.00137	CcSEcCtD
Methyl aminolevulinate—Rash—Conjugated Estrogens—prostate cancer	0.000932	0.00137	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Conjugated Estrogens—prostate cancer	0.000932	0.00137	CcSEcCtD
Methyl aminolevulinate—Headache—Conjugated Estrogens—prostate cancer	0.000926	0.00136	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—ITPR1—prostate cancer	0.00092	0.00289	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—JAK2—prostate cancer	0.000917	0.00288	CbGpPWpGaD
Methyl aminolevulinate—Infection—Etoposide—prostate cancer	0.000911	0.00134	CcSEcCtD
Methyl aminolevulinate—Erythema—Capecitabine—prostate cancer	0.000904	0.00133	CcSEcCtD
Methyl aminolevulinate—Nausea—Goserelin—prostate cancer	0.000887	0.0013	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—ITPR1—prostate cancer	0.000883	0.00277	CbGpPWpGaD
Methyl aminolevulinate—Nausea—Conjugated Estrogens—prostate cancer	0.000878	0.00129	CcSEcCtD
Methyl aminolevulinate—Urticaria—Mitoxantrone—prostate cancer	0.000876	0.00129	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Estradiol—prostate cancer	0.000872	0.00128	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—PIK3CB—prostate cancer	0.000871	0.00274	CbGpPWpGaD
Methyl aminolevulinate—Eye disorder—Prednisone—prostate cancer	0.000865	0.00127	CcSEcCtD
Methyl aminolevulinate—Asthenia—Estradiol—prostate cancer	0.000849	0.00125	CcSEcCtD
Methyl aminolevulinate—Pruritus—Estradiol—prostate cancer	0.000837	0.00123	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—PDGFRB—prostate cancer	0.000835	0.00262	CbGpPWpGaD
Methyl aminolevulinate—Photosensitivity reaction—Epirubicin—prostate cancer	0.000825	0.00121	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Etoposide—prostate cancer	0.000824	0.00121	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Mitoxantrone—prostate cancer	0.000813	0.00119	CcSEcCtD
Methyl aminolevulinate—Erythema—Prednisone—prostate cancer	0.000806	0.00118	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—PDGFRB—prostate cancer	0.000802	0.00252	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—IL2—prostate cancer	0.0008	0.00251	CbGpPWpGaD
Methyl aminolevulinate—Asthenia—Mitoxantrone—prostate cancer	0.000791	0.00116	CcSEcCtD
Methyl aminolevulinate—Fatigue—Etoposide—prostate cancer	0.000791	0.00116	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—ERBB3—prostate cancer	0.00079	0.00248	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—FGFR2—prostate cancer	0.000788	0.00248	CbGpPWpGaD
Methyl aminolevulinate—Pain—Etoposide—prostate cancer	0.000784	0.00115	CcSEcCtD
Methyl aminolevulinate—Dizziness—Estradiol—prostate cancer	0.000783	0.00115	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—B2M—prostate cancer	0.000767	0.00241	CbGpPWpGaD
Methyl aminolevulinate—Photosensitivity reaction—Doxorubicin—prostate cancer	0.000764	0.00112	CcSEcCtD
Methyl aminolevulinate—Oedema—Docetaxel—prostate cancer	0.000762	0.00112	CcSEcCtD
Methyl aminolevulinate—Discomfort—Capecitabine—prostate cancer	0.000761	0.00112	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—ERBB3—prostate cancer	0.000758	0.00238	CbGpPWpGaD
Methyl aminolevulinate—Infection—Docetaxel—prostate cancer	0.000757	0.00111	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—FGFR2—prostate cancer	0.000757	0.00238	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—PRKACB—prostate cancer	0.000751	0.00236	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—CTSB—prostate cancer	0.000747	0.00235	CbGpPWpGaD
Methyl aminolevulinate—Rash—Estradiol—prostate cancer	0.000746	0.00109	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Estradiol—prostate cancer	0.000746	0.00109	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—CTSD—prostate cancer	0.000743	0.00233	CbGpPWpGaD
Methyl aminolevulinate—Headache—Estradiol—prostate cancer	0.000741	0.00109	CcSEcCtD
Methyl aminolevulinate—Oedema—Capecitabine—prostate cancer	0.000738	0.00108	CcSEcCtD
Methyl aminolevulinate—Infection—Capecitabine—prostate cancer	0.000733	0.00108	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—PPP3CA—prostate cancer	0.000732	0.0023	CbGpPWpGaD
Methyl aminolevulinate—Urticaria—Etoposide—prostate cancer	0.000729	0.00107	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—BCL2L1—prostate cancer	0.000727	0.00228	CbGpPWpGaD
Methyl aminolevulinate—Nausea—Estradiol—prostate cancer	0.000703	0.00103	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—IL1RN—prostate cancer	0.000699	0.00219	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—CALR—prostate cancer	0.000696	0.00219	CbGpPWpGaD
Methyl aminolevulinate—Rash—Mitoxantrone—prostate cancer	0.000695	0.00102	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Mitoxantrone—prostate cancer	0.000695	0.00102	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—TLR4—prostate cancer	0.000692	0.00217	CbGpPWpGaD
Methyl aminolevulinate—Headache—Mitoxantrone—prostate cancer	0.000691	0.00101	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Docetaxel—prostate cancer	0.000685	0.001	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—FGFR4—prostate cancer	0.000684	0.00215	CbGpPWpGaD
Methyl aminolevulinate—Discomfort—Prednisone—prostate cancer	0.000678	0.000994	CcSEcCtD
Methyl aminolevulinate—Eye disorder—Epirubicin—prostate cancer	0.000676	0.000992	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Etoposide—prostate cancer	0.000676	0.000992	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—STAT3—prostate cancer	0.000673	0.00211	CbGpPWpGaD
Methyl aminolevulinate—Paraesthesia—Capecitabine—prostate cancer	0.000663	0.000972	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—BAD—prostate cancer	0.000658	0.00207	CbGpPWpGaD
Methyl aminolevulinate—Asthenia—Etoposide—prostate cancer	0.000658	0.000966	CcSEcCtD
Methyl aminolevulinate—Oedema—Prednisone—prostate cancer	0.000657	0.000965	CcSEcCtD
Methyl aminolevulinate—Fatigue—Docetaxel—prostate cancer	0.000657	0.000964	CcSEcCtD
Methyl aminolevulinate—Nausea—Mitoxantrone—prostate cancer	0.000655	0.000961	CcSEcCtD
Methyl aminolevulinate—Infection—Prednisone—prostate cancer	0.000653	0.000958	CcSEcCtD
Methyl aminolevulinate—Pain—Docetaxel—prostate cancer	0.000652	0.000956	CcSEcCtD
Methyl aminolevulinate—Pruritus—Etoposide—prostate cancer	0.000649	0.000952	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—ICAM1—prostate cancer	0.000637	0.002	CbGpPWpGaD
Methyl aminolevulinate—Fatigue—Capecitabine—prostate cancer	0.000636	0.000934	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—BAD—prostate cancer	0.000632	0.00199	CbGpPWpGaD
Methyl aminolevulinate—Pain—Capecitabine—prostate cancer	0.000631	0.000926	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—IRS1—prostate cancer	0.00063	0.00198	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—EGF—prostate cancer	0.00063	0.00198	CbGpPWpGaD
Methyl aminolevulinate—Erythema—Epirubicin—prostate cancer	0.00063	0.000924	CcSEcCtD
Methyl aminolevulinate—Eye disorder—Doxorubicin—prostate cancer	0.000626	0.000918	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—CASP9—prostate cancer	0.000622	0.00195	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—GSK3B—prostate cancer	0.000612	0.00192	CbGpPWpGaD
Methyl aminolevulinate—Dizziness—Etoposide—prostate cancer	0.000607	0.00089	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—EGR1—prostate cancer	0.000606	0.0019	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—EGF—prostate cancer	0.000605	0.0019	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—IRS1—prostate cancer	0.000605	0.0019	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—PRKCQ—prostate cancer	0.000602	0.00189	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—MAP3K7—prostate cancer	0.000595	0.00187	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—CREBBP—prostate cancer	0.000591	0.00186	CbGpPWpGaD
Methyl aminolevulinate—Paraesthesia—Prednisone—prostate cancer	0.00059	0.000866	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—GSK3B—prostate cancer	0.000588	0.00185	CbGpPWpGaD
Methyl aminolevulinate—Urticaria—Capecitabine—prostate cancer	0.000586	0.00086	CcSEcCtD
Methyl aminolevulinate—Erythema—Doxorubicin—prostate cancer	0.000583	0.000855	CcSEcCtD
Methyl aminolevulinate—Rash—Etoposide—prostate cancer	0.000578	0.000849	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—KRAS—prostate cancer	0.000578	0.00182	CbGpPWpGaD
Methyl aminolevulinate—Dermatitis—Etoposide—prostate cancer	0.000578	0.000848	CcSEcCtD
Methyl aminolevulinate—Headache—Etoposide—prostate cancer	0.000575	0.000843	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—FGF10—prostate cancer	0.000572	0.0018	CbGpPWpGaD
Methyl aminolevulinate—Fatigue—Prednisone—prostate cancer	0.000567	0.000832	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—MAP2K1—prostate cancer	0.000564	0.00177	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—CDH1—prostate cancer	0.000564	0.00177	CbGpPWpGaD
Methyl aminolevulinate—Hypersensitivity—Docetaxel—prostate cancer	0.000562	0.000824	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—PIK3CD—prostate cancer	0.000561	0.00176	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—VAV3—prostate cancer	0.000552	0.00173	CbGpPWpGaD
Methyl aminolevulinate—Asthenia—Docetaxel—prostate cancer	0.000547	0.000802	CcSEcCtD
Methyl aminolevulinate—Nausea—Etoposide—prostate cancer	0.000545	0.000799	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Capecitabine—prostate cancer	0.000544	0.000798	CcSEcCtD
Methyl aminolevulinate—Pruritus—Docetaxel—prostate cancer	0.000539	0.000791	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—PIK3CD—prostate cancer	0.000538	0.00169	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—FGF2—prostate cancer	0.000537	0.00169	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—ITPR1—prostate cancer	0.000536	0.00168	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—PIK3CA—prostate cancer	0.000531	0.00167	CbGpPWpGaD
Methyl aminolevulinate—Discomfort—Epirubicin—prostate cancer	0.00053	0.000778	CcSEcCtD
Methyl aminolevulinate—Asthenia—Capecitabine—prostate cancer	0.00053	0.000777	CcSEcCtD
Methyl aminolevulinate—Urticaria—Prednisone—prostate cancer	0.000522	0.000766	CcSEcCtD
Methyl aminolevulinate—Pruritus—Capecitabine—prostate cancer	0.000522	0.000766	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—FGF2—prostate cancer	0.000515	0.00162	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—JAK2—prostate cancer	0.000514	0.00162	CbGpPWpGaD
Methyl aminolevulinate—Oedema—Epirubicin—prostate cancer	0.000514	0.000754	CcSEcCtD
Methyl aminolevulinate—Infection—Epirubicin—prostate cancer	0.000511	0.000749	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—BCL2—prostate cancer	0.00051	0.0016	CbGpPWpGaD
Methyl aminolevulinate—Dizziness—Docetaxel—prostate cancer	0.000504	0.00074	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—MDM2—prostate cancer	0.000502	0.00158	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—IL18—prostate cancer	0.000502	0.00158	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—ERBB2—prostate cancer	0.000495	0.00156	CbGpPWpGaD
Methyl aminolevulinate—Discomfort—Doxorubicin—prostate cancer	0.00049	0.000719	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—PIK3CB—prostate cancer	0.000489	0.00153	CbGpPWpGaD
Methyl aminolevulinate—Dizziness—Capecitabine—prostate cancer	0.000488	0.000716	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—PDGFRB—prostate cancer	0.000487	0.00153	CbGpPWpGaD
Methyl aminolevulinate—Hypersensitivity—Prednisone—prostate cancer	0.000484	0.000711	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—MDM2—prostate cancer	0.000482	0.00151	CbGpPWpGaD
Methyl aminolevulinate—Rash—Docetaxel—prostate cancer	0.000481	0.000705	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Docetaxel—prostate cancer	0.00048	0.000705	CcSEcCtD
Methyl aminolevulinate—Headache—Docetaxel—prostate cancer	0.000478	0.000701	CcSEcCtD
Methyl aminolevulinate—Oedema—Doxorubicin—prostate cancer	0.000476	0.000698	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—ERBB2—prostate cancer	0.000475	0.00149	CbGpPWpGaD
Methyl aminolevulinate—Infection—Doxorubicin—prostate cancer	0.000473	0.000693	CcSEcCtD
Methyl aminolevulinate—Asthenia—Prednisone—prostate cancer	0.000472	0.000692	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—IL6—prostate cancer	0.00047	0.00148	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—PIK3CB—prostate cancer	0.000469	0.00147	CbGpPWpGaD
Methyl aminolevulinate—Rash—Capecitabine—prostate cancer	0.000465	0.000683	CcSEcCtD
Methyl aminolevulinate—Pruritus—Prednisone—prostate cancer	0.000465	0.000682	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Capecitabine—prostate cancer	0.000465	0.000682	CcSEcCtD
Methyl aminolevulinate—Headache—Capecitabine—prostate cancer	0.000462	0.000678	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Epirubicin—prostate cancer	0.000462	0.000677	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—ERBB3—prostate cancer	0.00046	0.00144	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—FGFR2—prostate cancer	0.000459	0.00144	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—CDKN1B—prostate cancer	0.000459	0.00144	CbGpPWpGaD
Methyl aminolevulinate—Nausea—Docetaxel—prostate cancer	0.000453	0.000664	CcSEcCtD
Methyl aminolevulinate—Fatigue—Epirubicin—prostate cancer	0.000443	0.00065	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—CDKN1B—prostate cancer	0.00044	0.00138	CbGpPWpGaD
Methyl aminolevulinate—Pain—Epirubicin—prostate cancer	0.00044	0.000645	CcSEcCtD
Methyl aminolevulinate—Nausea—Capecitabine—prostate cancer	0.000438	0.000643	CcSEcCtD
Methyl aminolevulinate—Dizziness—Prednisone—prostate cancer	0.000435	0.000638	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—CTNNB1—prostate cancer	0.000433	0.00136	CbGpPWpGaD
Methyl aminolevulinate—Paraesthesia—Doxorubicin—prostate cancer	0.000427	0.000627	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—CDKN1A—prostate cancer	0.000423	0.00133	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—BCL2L1—prostate cancer	0.000423	0.00133	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—PTEN—prostate cancer	0.000422	0.00133	CbGpPWpGaD
Methyl aminolevulinate—Rash—Prednisone—prostate cancer	0.000415	0.000608	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Prednisone—prostate cancer	0.000414	0.000608	CcSEcCtD
Methyl aminolevulinate—Headache—Prednisone—prostate cancer	0.000412	0.000604	CcSEcCtD
Methyl aminolevulinate—Fatigue—Doxorubicin—prostate cancer	0.00041	0.000602	CcSEcCtD
Methyl aminolevulinate—Urticaria—Epirubicin—prostate cancer	0.000409	0.000599	CcSEcCtD
Methyl aminolevulinate—Pain—Doxorubicin—prostate cancer	0.000407	0.000597	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—CDKN1A—prostate cancer	0.000406	0.00128	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—PTEN—prostate cancer	0.000405	0.00127	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—TLR4—prostate cancer	0.000403	0.00127	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—EP300—prostate cancer	0.000403	0.00126	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—SRC—prostate cancer	0.000392	0.00123	CbGpPWpGaD
Methyl aminolevulinate—Nausea—Prednisone—prostate cancer	0.000391	0.000573	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—ICAM1—prostate cancer	0.000387	0.00121	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—BAD—prostate cancer	0.000383	0.0012	CbGpPWpGaD
Methyl aminolevulinate—Hypersensitivity—Epirubicin—prostate cancer	0.000379	0.000556	CcSEcCtD
Methyl aminolevulinate—Urticaria—Doxorubicin—prostate cancer	0.000378	0.000555	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—SRC—prostate cancer	0.000376	0.00118	CbGpPWpGaD
Methyl aminolevulinate—Asthenia—Epirubicin—prostate cancer	0.000369	0.000541	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—EGF—prostate cancer	0.000367	0.00115	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—IRS1—prostate cancer	0.000367	0.00115	CbGpPWpGaD
Methyl aminolevulinate—Pruritus—Epirubicin—prostate cancer	0.000364	0.000534	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—GSK3B—prostate cancer	0.000356	0.00112	CbGpPWpGaD
Methyl aminolevulinate—Hypersensitivity—Doxorubicin—prostate cancer	0.000351	0.000514	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—CREBBP—prostate cancer	0.000344	0.00108	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—EGFR—prostate cancer	0.000343	0.00108	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—CDH1—prostate cancer	0.000342	0.00107	CbGpPWpGaD
Methyl aminolevulinate—Asthenia—Doxorubicin—prostate cancer	0.000341	0.000501	CcSEcCtD
Methyl aminolevulinate—Dizziness—Epirubicin—prostate cancer	0.00034	0.000499	CcSEcCtD
Methyl aminolevulinate—Pruritus—Doxorubicin—prostate cancer	0.000337	0.000494	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—EGFR—prostate cancer	0.00033	0.00104	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—MAP2K1—prostate cancer	0.000329	0.00103	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—PIK3CD—prostate cancer	0.000326	0.00103	CbGpPWpGaD
Methyl aminolevulinate—Rash—Epirubicin—prostate cancer	0.000324	0.000476	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—KRAS—prostate cancer	0.000324	0.00102	CbGpPWpGaD
Methyl aminolevulinate—Dermatitis—Epirubicin—prostate cancer	0.000324	0.000475	CcSEcCtD
Methyl aminolevulinate—Headache—Epirubicin—prostate cancer	0.000322	0.000473	CcSEcCtD
Methyl aminolevulinate—Dizziness—Doxorubicin—prostate cancer	0.000315	0.000462	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—FGF2—prostate cancer	0.000313	0.000982	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—KRAS—prostate cancer	0.000311	0.000978	CbGpPWpGaD
Methyl aminolevulinate—Nausea—Epirubicin—prostate cancer	0.000305	0.000448	CcSEcCtD
Methyl aminolevulinate—Rash—Doxorubicin—prostate cancer	0.0003	0.00044	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Doxorubicin—prostate cancer	0.0003	0.00044	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—JAK2—prostate cancer	0.0003	0.000941	CbGpPWpGaD
Methyl aminolevulinate—Headache—Doxorubicin—prostate cancer	0.000298	0.000437	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—PIK3CA—prostate cancer	0.000298	0.000936	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—BCL2—prostate cancer	0.000297	0.000932	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—MDM2—prostate cancer	0.000292	0.000919	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—ERBB2—prostate cancer	0.000288	0.000906	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—PIK3CA—prostate cancer	0.000286	0.000898	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—PIK3CB—prostate cancer	0.000285	0.000894	CbGpPWpGaD
Methyl aminolevulinate—Nausea—Doxorubicin—prostate cancer	0.000283	0.000415	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—CDKN1B—prostate cancer	0.000267	0.000839	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—IL6—prostate cancer	0.000264	0.000828	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—IL2—prostate cancer	0.000261	0.000821	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—CTNNB1—prostate cancer	0.000252	0.000792	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—CDKN1A—prostate cancer	0.000246	0.000774	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—PTEN—prostate cancer	0.000246	0.000772	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—AKT1—prostate cancer	0.000243	0.000764	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—EP300—prostate cancer	0.000235	0.000737	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—AKT1—prostate cancer	0.000234	0.000734	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—SRC—prostate cancer	0.000228	0.000716	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—STAT3—prostate cancer	0.00022	0.000691	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—EGFR—prostate cancer	0.0002	0.000628	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—KRAS—prostate cancer	0.000189	0.000593	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—PIK3CA—prostate cancer	0.000173	0.000545	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—IL6—prostate cancer	0.000154	0.000482	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—AKT1—prostate cancer	0.000142	0.000445	CbGpPWpGaD
